Published in Cell on September 21, 2007
Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64
IRF4 addiction in multiple myeloma. Nature (2008) 6.27
Cancer proliferation gene discovery through functional genomics. Science (2008) 5.41
Signaling to p53: ribosomal proteins find their way. Cancer Cell (2009) 3.84
Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl Acad Sci U S A (2011) 3.20
HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell (2012) 2.94
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science (2013) 2.79
A small molecule inhibitor of inducible heat shock protein 70. Mol Cell (2009) 2.63
Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest (2009) 2.55
DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell (2012) 2.45
Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle (2009) 2.43
MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell (2010) 2.29
High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci U S A (2011) 2.03
Mutant KRAS Enhances Tumor Cell Fitness by Upregulating Stress Granules. Cell (2016) 2.03
Cancer vulnerabilities unveiled by genomic loss. Cell (2012) 1.95
Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival. Nature (2008) 1.91
Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res (2008) 1.88
Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin Cancer Res (2010) 1.81
IRF4: Immunity. Malignancy! Therapy? Clin Cancer Res (2009) 1.61
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Targeting HSP90 for cancer therapy. Br J Cancer (2009) 1.44
An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell (2016) 1.43
NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget (2011) 1.42
IKK{gamma} protein is a target of BAG3 regulatory activity in human tumor growth. Proc Natl Acad Sci U S A (2010) 1.36
Using the heat-shock response to discover anticancer compounds that target protein homeostasis. ACS Chem Biol (2011) 1.31
Phosphorylation of human TFAM in mitochondria impairs DNA binding and promotes degradation by the AAA+ Lon protease. Mol Cell (2012) 1.28
Cancer research: past, present and future. Nat Rev Cancer (2011) 1.24
Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance. Cancer Res (2013) 1.19
KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter. J Biol Chem (2010) 1.18
Diacylglycerol kinase α is a critical signaling node and novel therapeutic target in glioblastoma and other cancers. Cancer Discov (2013) 1.16
Transcriptional response to stress in the dynamic chromatin environment of cycling and mitotic cells. Proc Natl Acad Sci U S A (2013) 1.15
The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis. Cell Death Differ (2011) 1.10
Targeting translation dependence in cancer. Oncotarget (2011) 1.09
Englerin A stimulates PKCθ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality. Cancer Cell (2013) 1.08
Heat shock protein Hsp72 plays an essential role in Her2-induced mammary tumorigenesis. Oncogene (2011) 1.06
Emerging therapeutics targeting mRNA translation. Cold Spring Harb Perspect Biol (2012) 1.04
Targeting HSF1 sensitizes cancer cells to HSP90 inhibition. Oncotarget (2013) 1.02
Targeting the RAS oncogene. Expert Opin Ther Targets (2013) 1.02
Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. EMBO Mol Med (2015) 1.00
Heat shock transcription factor Hsf1 is involved in tumor progression via regulation of hypoxia-inducible factor 1 and RNA-binding protein HuR. Mol Cell Biol (2012) 0.98
Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92/106b-25 clusters. Mol Cancer Ther (2012) 0.96
Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics. ACS Med Chem Lett (2012) 0.90
Activation of heat shock factor 1 plays a role in pyrrolidine dithiocarbamate-mediated expression of the co-chaperone BAG3. Int J Biochem Cell Biol (2010) 0.90
Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogrammed primary prostate cancer cells. Oncotarget (2014) 0.90
Signal transduction in cancer. Cold Spring Harb Perspect Med (2015) 0.88
Expression of HSF2 decreases in mitosis to enable stress-inducible transcription and cell survival. J Cell Biol (2014) 0.87
Systems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and "swarm intelligence". Cancer Metastasis Rev (2013) 0.86
Drugging the addict: non-oncogene addiction as a target for cancer therapy. EMBO Rep (2016) 0.84
HIV-1 Rev-binding protein accelerates cellular uptake of iron to drive Notch-induced T cell leukemogenesis in mice. J Clin Invest (2010) 0.84
MAPK15 upregulation promotes cell proliferation and prevents DNA damage in male germ cell tumors. Oncotarget (2016) 0.84
Small molecule-induced mitochondrial disruption directs prostate cancer inhibition via UPR signaling. Oncotarget (2013) 0.84
Pilot study of p62 DNA vaccine in dogs with mammary tumors. Oncotarget (2014) 0.84
ERLIN2 promotes breast cancer cell survival by modulating endoplasmic reticulum stress pathways. BMC Cancer (2012) 0.83
Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83
Inducible hsp70 in the regulation of cancer cell survival: analysis of chaperone induction, expression and activity. Cancers (Basel) (2011) 0.83
Molecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage response. Clin Cancer Res (2014) 0.83
Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy. Int Rev Immunol (2014) 0.82
A network flow-based method to predict anticancer drug sensitivity. PLoS One (2015) 0.81
Protease addiction and synthetic lethality in cancer. Front Oncol (2011) 0.81
Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery. Mol Ther (2014) 0.81
FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification. Nat Cell Biol (2015) 0.81
Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A. Cell Mol Life Sci (2011) 0.81
Protein ubiquitination in lymphoid malignancies. Immunol Rev (2015) 0.80
CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer. Breast Cancer Res Treat (2015) 0.80
Heat-shock factor 2 is a suppressor of prostate cancer invasion. Oncogene (2015) 0.80
Past, present, and future of molecular and cellular oncology. Front Oncol (2011) 0.80
Targeting p97 to Disrupt Protein Homeostasis in Cancer. Front Oncol (2016) 0.79
Sequential cytoprotective responses to Sigma1 ligand-induced endoplasmic reticulum stress. Mol Pharmacol (2013) 0.79
The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors. J Proteome Res (2013) 0.79
Elevated DDX21 regulates c-Jun activity and rRNA processing in human breast cancers. Breast Cancer Res (2014) 0.79
Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover. Genes Dev (2016) 0.78
Proteotoxic stress targeted therapy (PSTT). Oncotarget (2011) 0.78
Pleiotropic role of HSF1 in neoplastic transformation. Curr Cancer Drug Targets (2014) 0.78
Using functional genomics to overcome therapeutic resistance in hematological malignancies. Immunol Res (2013) 0.78
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers (Basel) (2017) 0.77
From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond. Genes Cancer (2010) 0.77
Targeting CK2-driven non-oncogene addiction in B-cell tumors. Oncogene (2016) 0.77
Identification of mixed lineage leukemia 1(MLL1) protein as a coactivator of heat shock factor 1(HSF1) protein in response to heat shock protein 90 (HSP90) inhibition. J Biol Chem (2014) 0.77
Mitochondrial mutations and metabolic adaptation in pancreatic cancer. Cancer Metab (2017) 0.77
Targeting a cell state common to triple-negative breast cancers. Mol Syst Biol (2015) 0.77
Elevation of proteasomal substrate levels sensitizes cells to apoptosis induced by inhibition of proteasomal deubiquitinases. PLoS One (2014) 0.76
Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer. Oncotarget (2016) 0.76
Overexpression of hepatoma-derived growth factor in melanocytes does not lead to oncogenic transformation. BMC Cancer (2011) 0.75
Proteotoxicity is not the reason for the dependence of cancer cells on the major chaperone Hsp70. Cell Cycle (2014) 0.75
Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol (2014) 0.75
Drug therapy: Exploiting synthetic lethality to improve cancer therapy. Nat Rev Clin Oncol (2017) 0.75
Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice. PLoS One (2017) 0.75
USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer. J Biol Chem (2017) 0.75
High Energy Particle Radiation-associated Oncogenic Transformation in Normal Mice: Insight into the Connection between Activation of Oncotargets and Oncogene Addiction. Sci Rep (2016) 0.75
Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents. Curr Probl Cancer (2013) 0.75
cDNA microarray analysis of the effect of cantharidin on DNA damage, cell cycle and apoptosis-associated gene expression in NCI-H460 human lung cancer cells in vitro. Mol Med Rep (2015) 0.75
The Hippo Pathway Targets Rae1 to Regulate Mitosis and Organ Size and to Feed Back to Regulate Upstream Components Merlin, Hippo, and Warts. PLoS Genet (2016) 0.75
Proteasome activity is required for the initiation of precancerous pancreatic lesions. Sci Rep (2016) 0.75
Functional genomic screening to enhance oncolytic virotherapy. Br J Cancer (2012) 0.75
High-throughput screening system for inhibitors of human Heat Shock Factor 2. Cell Stress Chaperones (2015) 0.75
Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach. Int J Mol Sci (2017) 0.75
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science (2007) 20.11
Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science (2003) 18.29
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
The DNA damage response: making it safe to play with knives. Mol Cell (2010) 16.13
Dicer is essential for mouse development. Nat Genet (2003) 15.87
Identification of host proteins required for HIV infection through a functional genomic screen. Science (2008) 12.44
The DNA damage response: ten years after. Mol Cell (2007) 11.80
Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96
Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature (2002) 10.96
A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A (2008) 10.07
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64
Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet (2005) 8.23
The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell (2009) 7.88
Harnessing homologous recombination in vitro to generate recombinant DNA via SLIC. Nat Methods (2007) 7.56
MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature (2003) 6.81
Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science (2007) 6.77
Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell (2007) 6.68
A resource for large-scale RNA-interference-based screens in mammals. Nature (2004) 6.36
A genetic screen for candidate tumor suppressors identifies REST. Cell (2005) 5.61
Cancer proliferation gene discovery through functional genomics. Science (2008) 5.41
Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell (2009) 5.41
A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A (2005) 5.29
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res (2005) 5.07
53BP1, a mediator of the DNA damage checkpoint. Science (2002) 5.00
RNA interference screen for human genes associated with West Nile virus infection. Nature (2008) 4.93
The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science (2009) 4.85
BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3. Nature (2003) 4.79
Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc Natl Acad Sci U S A (2007) 4.75
Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev (2004) 4.68
Regulation of ATR substrate selection by Rad17-dependent loading of Rad9 complexes onto chromatin. Genes Dev (2002) 4.58
Profiling essential genes in human mammary cells by multiplex RNAi screening. Science (2008) 4.51
A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal. Genes Dev (2009) 4.23
Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature (2007) 4.14
Global protein stability profiling in mammalian cells. Science (2008) 3.91
Replication protein A-mediated recruitment and activation of Rad17 complexes. Proc Natl Acad Sci U S A (2003) 3.88
Checking on the fork: the DNA-replication stress-response pathway. Trends Cell Biol (2002) 3.66
The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol (2007) 3.63
Mrc1 is a replication fork component whose phosphorylation in response to DNA replication stress activates Rad53. Genes Dev (2003) 3.59
A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. Mol Cell (2010) 3.51
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49
Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science (2012) 3.41
The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A (2011) 3.40
A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A (2009) 3.37
SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev (2003) 3.35
A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. Proc Natl Acad Sci U S A (2010) 3.31
Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell (2011) 3.27
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog (2011) 3.26
Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell (2013) 3.26
Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc Natl Acad Sci U S A (2012) 3.24
NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. Genes Dev (2009) 3.23
FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. Nat Struct Mol Biol (2008) 3.22
Global identification of modular cullin-RING ligase substrates. Cell (2011) 3.13
Minichromosome maintenance proteins are direct targets of the ATM and ATR checkpoint kinases. Proc Natl Acad Sci U S A (2004) 3.12
A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell (2006) 3.10
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol (2002) 3.08
IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog (2011) 2.99
Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell (2004) 2.94
WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity. Nature (2008) 2.86
The SUMO-1 isopeptidase Smt4 is linked to centromeric cohesion through SUMO-1 modification of DNA topoisomerase II. Mol Cell (2002) 2.85
SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature (2008) 2.84
Multiple tumor suppressor pathways negatively regulate telomerase. Cell (2003) 2.82
Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell (2011) 2.82
Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab (2006) 2.82
Lessons from Nature: microRNA-based shRNA libraries. Nat Methods (2006) 2.80
Acute effects of leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons in mice. J Clin Invest (2008) 2.77
Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc Natl Acad Sci U S A (2004) 2.66
MAGIC, an in vivo genetic method for the rapid construction of recombinant DNA molecules. Nat Genet (2005) 2.63
Design of 240,000 orthogonal 25mer DNA barcode probes. Proc Natl Acad Sci U S A (2009) 2.61
The mitotic spindle is required for loading of the DASH complex onto the kinetochore. Genes Dev (2002) 2.60
Identification of SCF ubiquitin ligase substrates by global protein stability profiling. Science (2008) 2.53
A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. Nat Cell Biol (2012) 2.51
The SIOD disorder protein SMARCAL1 is an RPA-interacting protein involved in replication fork restart. Genes Dev (2009) 2.44
Towards genetic genome projects: genomic library screening and gene-targeting vector construction in a single step. Nat Genet (2001) 2.21
An open letter to Elias Zerhouni. Science (2005) 2.19
FANCM and FAAP24 function in ATR-mediated checkpoint signaling independently of the Fanconi anemia core complex. Mol Cell (2008) 2.14
Role for the BRCA1 C-terminal repeats (BRCT) protein 53BP1 in maintaining genomic stability. J Biol Chem (2003) 2.03
A functional genomic screen identifies a role for TAO1 kinase in spindle-checkpoint signalling. Nat Cell Biol (2007) 2.00
A genetic screen identifies the Triple T complex required for DNA damage signaling and ATM and ATR stability. Genes Dev (2010) 1.98
CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation. Mol Cell (2008) 1.94
Autoantigen discovery with a synthetic human peptidome. Nat Biotechnol (2011) 1.90
BRIT1/MCPH1 is a DNA damage responsive protein that regulates the Brca1-Chk1 pathway, implicating checkpoint dysfunction in microcephaly. Proc Natl Acad Sci U S A (2005) 1.90
Recruitment of fanconi anemia and breast cancer proteins to DNA damage sites is differentially governed by replication. Mol Cell (2009) 1.85
Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep (2012) 1.84
Tipin and Timeless form a mutually protective complex required for genotoxic stress resistance and checkpoint function. Proc Natl Acad Sci U S A (2006) 1.81
A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1 interacting protein required for ATR signaling. Science (2011) 1.79
RIDDLE immunodeficiency syndrome is linked to defects in 53BP1-mediated DNA damage signaling. Proc Natl Acad Sci U S A (2007) 1.79
Polyubiquitinated PCNA recruits the ZRANB3 translocase to maintain genomic integrity after replication stress. Mol Cell (2012) 1.79
Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN. Proc Natl Acad Sci U S A (2006) 1.79
Systematic identification of synergistic drug pairs targeting HIV. Nat Biotechnol (2012) 1.77
Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proc Natl Acad Sci U S A (2010) 1.76
Recognition of phosphodegron motifs in human cyclin E by the SCF(Fbw7) ubiquitin ligase. J Biol Chem (2004) 1.74
The Prp19 complex and the Usp4Sart3 deubiquitinating enzyme control reversible ubiquitination at the spliceosome. Genes Dev (2010) 1.74
Wnt signaling regulates mitochondrial physiology and insulin sensitivity. Genes Dev (2010) 1.71
Genetic and physical interactions between DPB11 and DDC1 in the yeast DNA damage response pathway. Genetics (2002) 1.66